Literature DB >> 27749637

Biodegradable Stents: An Evolution in Management of Benign Intestinal Strictures.

Deepanshu Jain1, Ejaz Mahmood, Shashideep Singhal.   

Abstract

Benign intestine strictures secondary to postoperative narrowing or inflammatory bowel disease can be managed surgically or conservatively. Some patients may not be suitable surgical candidates and some patients may choose not to have repeat surgery. Biodegradable (BD) stents offer a prolonged dilatory effect before gradual degradation and obviates the need of a second procedure for stent removal. BD stents have high technical success rates (mean, 94.4%; median, 100%; range, 86% to 100%) but widely variable clinical success rates (range, 45% to 100%). Stent migration is the most commonly reported complication (mean, 22.2%; range, 0% to 36%). In the future, with better understanding of the factors contributing to stent migration, improvement in present stent design and better anchoring techniques, the stent migration rate is expected to decrease and improve clinical outcome. The role of prophylactic BD stent placement to prevent stricture development postintestine surgery is an intriguing idea and needs to be explored. As of now, the use of BD stents is a reasonable option for patients with dilatation resistant intestinal strictures who are unfit for surgery or refuse to have surgical treatment.

Entities:  

Mesh:

Year:  2017        PMID: 27749637     DOI: 10.1097/MCG.0000000000000725

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  2 in total

1.  Endoscopic stricturotomy with pulsed argon plasma and balloon dilation for refractory benign colorectal strictures: a case series.

Authors:  Saad Emhmed Ali; Avinash Bhakta; Robert-Marlo Bautista; Ahmed Sherif; Wesam Frandah
Journal:  Transl Gastroenterol Hepatol       Date:  2022-07-25

2.  Biological behavior exploration of a paclitaxel-eluting poly-l-lactide-coated Mg-Zn-Y-Nd alloy intestinal stent in vivo.

Authors:  Zhanhui Wang; Zongbin Sun; Baowei Han; Qiuxia Zheng; Shaopeng Liu; Bingbing Zhang; Tinghe Duan
Journal:  RSC Adv       Date:  2020-04-16       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.